Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
AstraZeneca
Baxter
Harvard Business School
Boehringer Ingelheim

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020990


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 020990 describes ZOLOFT, which is a drug marketed by Pfizer and is included in two NDAs. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ZOLOFT profile page.

The generic ingredient in ZOLOFT is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.
Summary for 020990
Tradename:ZOLOFT
Applicant:Pfizer
Ingredient:sertraline hydrochloride
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 020990
Mechanism of ActionSerotonin Uptake Inhibitors
Medical Subject Heading (MeSH) Categories for 020990
Suppliers and Packaging for NDA: 020990
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990 NDA Roerig 0049-0050 0049-0050-01 1 BOTTLE, DROPPER in 1 CARTON (0049-0050-01) > 60 mL in 1 BOTTLE, DROPPER
ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990 NDA AUTHORIZED GENERIC Greenstone LLC 59762-0067 59762-0067-1 60 mL in 1 BOTTLE, DROPPER (59762-0067-1)
Paragraph IV (Patent) Challenges for 020990
Tradename Dosage Ingredient NDA Submissiondate
ZOLOFT CONCENTRATE;ORAL sertraline hydrochloride 020990 2003-12-09

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CONCENTRATE;ORALStrengthEQ 20MG BASE/ML
Approval Date:Dec 7, 1999TE:AARLD:Yes
Patent:  Start TrialPatent Expiration:Apr 11, 2020Product Flag?Substance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Apr 11, 2020Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020990

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999   Start Trial   Start Trial
Pfizer ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999   Start Trial   Start Trial
Pfizer ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999   Start Trial   Start Trial
Pfizer ZOLOFT sertraline hydrochloride CONCENTRATE;ORAL 020990-001 Dec 7, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Medtronic
Boehringer Ingelheim
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.